In Australian intensive care units Candida spp. cause 80 % of hospital acquired infections and contribute to a mortality rate over 50 % from Candidaemia (Marriott et al. 2006). New antifungal surfaces directed at minimising the adhesion of the Candida spp. to catheters and other medical devices could increase patient welfare and decrease health-care costs. We developed a novel surface coating using the antifungal caspofungin covalently bonded to the material surface, which demonstrated significant antifungal activity against various Candida spp. (Coad et al. 2015). We found that biofilm formation on caspofungin surfaces was delayed for both typed and clinical Candida strains showing significant difference when compared to untreated materials. Kinetic viability assays demonstrated that after 30 minutes C. albicans had minimal adhesion on caspofungin surfaces and after 60 minutes significant cell death was seen. For eventual clinical use, it is important to investigate the potential loss of activity that could occur through heat sterilisation and fouling by host proteins. We have demonstrated that caspofungin coatings retain excellent activity after autoclaving. Furthermore, protein fouling with serum or BSA does not inhibit activity of the surface coating. These results indicate that surface coatings with covalently attached caspofungin could be promising for biomaterial implants.